Pre-exposure Prophylaxis for Transgender People: A Systematic Review-Reference-Cited by-同舟云学术

Pre-exposure Prophylaxis for Transgender People: A Systematic Review

Published:2024-04-24 Issue: Volume: Page:
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Perez-Alba Eduardo¹^ORCID,Iquize-Condori Roxana Claudia¹,Cantú-Hernández Jorge Alberto²,Álvarez-Villalobos Neri Alejandro²,Salinas-Garza Luis Adrián¹,Camacho-Ortiz Adrián¹^ORCID

Affiliation:

1. Servicio de Infectología, Hospital Universitario Dr José Eleuterio González, Universidad Autónoma de Nuevo León , Monterrey , Mexico

2. Centro de Análisis Avanzado de Información 360, Hospital Universitario Dr José Eleuterio González, Universidad Autónoma de Nuevo León , Monterrey , Mexico

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae226/58144050/ciae226.pdf

Reference6 articles.

1. Type 1 human immunodeficiency virus (HIV-1) incidence, adherence, and drug resistance in individuals taking daily emtricitabine/tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: pooled analysis from 72 global studies;Landovitz;Clin Infect Dis,2024

2. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town trial): a randomised, open-label, phase 2 trial;Bekker;Lancet HIV,2018

3. Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (MSM) (HPTN 069/ACTG A5305);Gulick;J Infect Dis,2016

4. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial;Deutsch;Lancet HIV,2015

5. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial;Mayer;Lancet,2020